Immvira Bioscience Inc.

亦诺微医药

Clinical-stage biotechnology company developing and manufacturing oncolytic immunotherapies and engineered exosome therapies for cancer treatment, including a Phase II HSV-1-based oncolytic candidate for bladder cancer and head and neck squamous cell carcinoma.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Chapter 18A biotech